|View printer-friendly version|
|CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting|
“The occurrence of immune-related adverse events is emerging as the Achilles’ heel of cancer immunotherapy,” said
About the PROCLAIM-CX-072 Trial
More information about the trial is available at clinicaltrials.gov.
CytomX Therapeutics Forward-Looking Statements